Stockreport

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat [Yahoo! Finance]

Erasca, Inc.  (ERAS) 
PDF Erasca, Inc. ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasc [Read more]